Author:
Chen Wenjun,Li Liang,Ji Shuangmin,Song Xuyang,Lu Wei,Zhou Tianyan
Funder
National Natural Science Foundation of China
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,General Medicine
Reference35 articles.
1. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Théodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA, TAX 327 Investigators (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351(15):1502–1512
2. D'Amico AV (2014) US Food and Drug Administration approval of drugs for the treatment of prostate cancer: a new era has begun. J Clin Oncol Off J Am Soc Clin Oncol 32(4):362–364
3. Schilsky RL (2002) End points in cancer clinical trials and the drug approval process. Clin Cancer Res 8(4):935–938
4. Group F-NBW. BEST (Biomarkers, EndpointS, and other Tools) Resource. Silver Spring (MD): Food and Drug Administration (US); 2016
5. Prasad V, Kim C, Burotto M, Vandross A (2015) The strength of association between surrogate end points and survival in oncology: a systematic review of trial-level meta-analyses. JAMA Intern Med 175(8):1389–1398
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献